New executives to facilitate further growth

Four startups in the life sciences and ICT sectors have recently restructured their leadership teams, appointing new CEOs, CTOs, and CFOs to propel their growth ambitions. Notably, Cytosurge and beqom have said goodbye to their long-serving leaders, marking the start of a new era in the companies after more than a decade.

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, is advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet needs. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms of menopause with readouts expected in 2025. The company has strengthened its leadership team with the appointment of Michael Samar as Chief Financial Officer (CFO). Michael brings 25 years of experience in life sciences and biotech, serving as both a strategic partner and a financial advisor to growth-phase and impact-driven organizations while helping forge a culture of success.

Leadership transition at Cytosurge
Cytosurge AG, a biotech company pioneering innovative single-cell biopsies and cell-line engineering solutions, announces a leadership transition effective January 1, 2025. Simon Egli, previously Chief Commercial Officer, has been appointed CEO to advance the company’s next growth phase. He succeeds Pascal Behr, co-founder and CEO for 12 years, who remains on the Board of Directors. Egli is a seasoned business leader with over a decade of experience in the life sciences industry. Before joining Cytosurge, Simon held senior roles at INFORS HT, serving as Chief Commercial Officer and Global Sales Director, leading global sales operations and strategic initiatives. He also gained leadership experience as CEO of Infors USA, Inc., overseeing the company’s U.S. growth. Simon’s education was rooted in Switzerland, where he earned an International Executive MBA from the Rochester-Bern Executive Programs and a degree in Biotechnology from ZHAW Zurich University of Applied Sciences.

Beqom welcomes new CEO after 16 years
beqom, a leader in compensation management software with over 400 clients and empowering more than five million employees worldwide, has appointed Lars Pedersen as CEO, effective January 8, 2025, succeeding co-founder Fabio Ronga. Under Ronga's leadership since 2009, beqom expanded globally, serving clients in over 160 countries and becoming a leader in compensation and pay equity solutions. Through strategic acquisitions, including one in 2024 that boosted customer growth 7x, beqom has broadened its offerings and market presence, driving innovation in fair pay and HR transformation.
Lars Pedersen’s appointment signals a key moment for beqom’s growth. With extensive experience in scaling software companies and leading transformative growth, Lars combines technical expertise with strategic vision. His leadership is expected to strengthen beqom’s position in compensation and pay equity solutions while driving future innovation and expansion.

derma2go appoints CTO
Derma2go is a Swiss teledermatology platform that connects patients with leading dermatology experts from renowned university hospitals and medical practices. Established in 2018, the platform aims to provide high-quality online consultations for skin conditions, allowing patients to receive accurate diagnoses and treatment plans within hours, thereby eliminating the need for long waiting times in clinics. The service has gained traction in the DACH region (Germany, Austria, Switzerland) and is expanding further into Europe. To support its development, derma2go has welcomed Lukas Schramm to the team, assuming the position of Chief Product & Technology Officer. His passion for innovative solutions and experience with digital health services will play a vital role in bringing the company vision forward.

(Press release/RAN)